A Nonsecosteroidal Vitamin D Receptor Modulator Ameliorates Experimental Autoimmune Encephalomyelitis without Causing...

Area of Science:

• Immunology
• Endocrinology
• Pharmacology

Background:

• Psoriasis and other autoimmune diseases are often treated with Vitamin D receptor (VDR) agonists.
• 1,25-dihydroxyvitamin D3 [1,25-(OH)(2)D(3)] shows efficacy in autoimmune disease models but causes hypercalcemia due to intestinal VDR activation.
• Hypercalcemia limits the clinical use of VDR agonists for autoimmune conditions.

Purpose of the Study:

• To identify and characterize a novel VDR modulator (VDRM) with reduced calcemic activity.
• To evaluate the immunomodulatory effects of the VDRM, specifically its impact on T-helper cell balance and differentiation.
• To assess the therapeutic potential of the VDRM in a preclinical model of autoimmune disease.

Main Methods:

• Identification of a VDRM (compound A) with decreased transcriptional activity in intestinal cells.
• In vivo assessment of calcemic activity compared to 1,25-(OH)(2)D(3).
• Cytokine analysis to determine effects on T-helper cell populations (Th1, Th2, Th17).
• Evaluation of compound A in the experimental autoimmune encephalomyelitis (EAE) mouse model.

Main Results:

• Compound A demonstrated significantly less hypercalcemic activity compared to 1,25-(OH)(2)D(3).
• The VDRM modulated T-helper cell balance from Th1 to Th2 and inhibited Th17 differentiation.
• Oral administration of compound A effectively inhibited the induction and progression of EAE in mice.
• No hypercalcemia was observed in mice treated with compound A.

Conclusions:

• The novel VDRM, compound A, represents a promising therapeutic candidate for autoimmune diseases.
• Its reduced calcemic activity, due to lower intestinal VDR modulation, overcomes a key limitation of current VDR agonists.
• Compound A's immunomodulatory effects suggest potential for treating conditions like multiple sclerosis and rheumatoid arthritis.